192 related articles for article (PubMed ID: 23984807)
1. Targeting angiogenesis in renal cell carcinoma.
Posadas EM; Limvorasak S; Sharma S; Figlin RA
Expert Opin Pharmacother; 2013 Nov; 14(16):2221-36. PubMed ID: 23984807
[TBL] [Abstract][Full Text] [Related]
2. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapy in renal cell cancer.
Srinivasan R; Armstrong AJ; Dahut W; George DJ
BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
[TBL] [Abstract][Full Text] [Related]
5. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
6. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
7. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
8. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
9. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
11. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Figlin RA; Kaufmann I; Brechbiel J
Int J Cancer; 2013 Aug; 133(4):788-96. PubMed ID: 23319457
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
14. The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.
Poletto V; Rosti V; Biggiogera M; Guerra G; Moccia F; Porta C
Crit Rev Oncol Hematol; 2018 Dec; 132():89-99. PubMed ID: 30447930
[TBL] [Abstract][Full Text] [Related]
15. [PI3K-AKT-mTOR pathway and cancer].
Coutte L; Dreyer C; Sablin MP; Faivre S; Raymond E
Bull Cancer; 2012 Feb; 99(2):173-80. PubMed ID: 21742593
[TBL] [Abstract][Full Text] [Related]
16. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
Gao N; Nester RA; Sarkar MA
Toxicol Appl Pharmacol; 2004 Apr; 196(1):124-35. PubMed ID: 15050414
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
